Preventive mutant concentrations: A new parameter of antimicrobial activity with clinical value?;Concentración preventiva de mutantes: ¿Un nuevo parámetro de actividad antimicrobiana con valor clínico?

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 10, 2006, Pages 599-602

  Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; EDITORIAL; ESCHERICHIA COLI; MUTANT; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846463810     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13095369     Document Type: Editorial

References (31)

1. Cornaglia G, Lonnroth A, Struelens M. Report from the European Conference on the Role of Research in Combating Antibiotic Resistance, 2003. Clin Microbiol Infect. 2004;10:473-97.
2. MacKenzie FM, Struelens MJ, Towner KJ, Gould IM; ARPAC Steering Group; ARPAC Consensus Conference Participants. Report of the Consensus Conference on Antibiotic Resistance; Prevention and Control (ARPAC). Clin Microbiol Infect. 2005;11:938-54.
3. Harbarth S, Samore MH. Antimicrobial resistance determinants and future control. Emerg Infect Dis. 2005;11:794-801.
4. Cantón Moreno R, Coque González TM, Baquero Mochales F. Evolución y perspectivas futuras de la resistencia a los antimicrobianos. En: Auxina Ruiz V, Moreno Guillén S, editores. Tratado SEIMC de Enfermedades Infecciosas y Microbiología Clínica. Buenos Aires: Editorial Médica Panamericana; 2006. p. 177-88.
5. Lipsitch M, Samore MH. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis. 2002;8:347-54.
6. Baquero F, Negri MC. Selective compartments for resistant microorganisms in antibiotic gradients. Bioessays. 1997;19:731-6.
7. Blázquez J, Morosini MI, Negri MC, González-Leiza M, Baquero F. Single amino acid replacements at positions altered in naturally occurring extended-spectrum TEM beta-lactamases. Antimicrob Agents Chemother. 1995; 39:145-9.
8. Negri MC, Baquero F. In vitro selective concentrations of cefepime and ceftazidime for AmpC beta-lactamase hyperproducer Enterobacter cloacae variants. Clin Microbiol Infect. 1999;5 Suppl 1:25-8.
9. Baquero F, Negri MC, Morosini MI, Blázquez J. The antibiotic selective process: concentration-specific amplification of low-level resistant populations. Ciba Found Symp. 1997;207:93-105.
10. Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance. J Chemother. 1997;9 Suppl 3:29-37.
11. Baquero F. Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother. 1999;11 Suppl 1:35-43.
12. Drlica K. A strategy for fighting antibiotic resistance. ASM News. 2001; 67:27-33.
13. Dong Y, Zhao X, Domagala J, Drlica K. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob Agents Chemother. 1999;43:1756-8.
14. Drlica K. The mutant selection window and antimicrobial resistance. J Antimicrob Chemother. 2003;52:11-7.
15. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother. 2001;45:433-8.
16. Linde HJ, Lehn N. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother. 2004;53:252-7.
17. Cantón R, García-Castillo M, Morosini MI, Baquero MR, Oliver A, Baquero F. Mutant prevention concentration (MPC) of different antibiotics in mutator and non-mutator Pseudomonas aeruginosa populations from cystic fibrosis patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago. September, 2003. Libro de Resúmenes, resumen A-1320.
18. Hansen GT, Zhao X, Drlica K, Blondeau JM. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa. Int J Antimicrob Agents. 2006;27:120-4.
19. Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis. 2002;185:561-5.
20. Epstein BJ, Gums JG, Drlica K. The changing face of antibiotic prescribing: the mutant selection window. Ann Pharmacother. 2004;38:1675-82.
21. Sirvent E, Ruiz M, Rodríguez JC, Royo G. Estudio de la actividad comparada de varias fluoroquinolonas frente a Pseudomonas aeruginosa mediante la determinación de la concentración preventiva de mutantes (CPM). Enferm Infecc Microbiol Clin. 2006;24(10):603-7.
22. Drago L, De Vecchi E, Nicola L, Tocalli L, Gismondo MR. In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. J Antimicrob Chemother. 2005;56:353-9.
23. Macia MD, Borrell N, Segura M, Gómez C, Pérez JL, Oliver A. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50:975-83.
24. Tumkaya M, Atis S, Ozge C, Delialioglu N, Polat G, Kanik A. Relationship between airway colonization, inflammation and exacerbation frequency in COPD. Respir Med. 2006 (in press).
25. Browne AC, Vearncombe M, Sibbald RG. High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft. Ostomy Wound Manage. 2001;47:44-9.
26. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K. Mutant prevention concentration of garenoxarin (BMS-284756) for ciprofloxacin- susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003;47:1023-7.
27. Aguado-García JM, Martín-Herrero JE, Lumbreras-Bermejo C. Resistencias bacterianas y farmacodinámica como bases de la prescripción de antibióticos en infecciones respiratorias. Enferm Infecc Microbiol Clin. 2004;22:230-7.
28. Balter MS, La Forge J, Low DE, Mandell L, Grossman RF; Canadian Thoracic Society; Canadian Infectious Disease Society, Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Can Respir J. 2003;10 Suppl B:3-32.
29. Cantón R, Lode H, Graninger W, Milkovich G. Respiratory tract infections: at-risk patients, who are they? Implications for their management with levofloxacin. Int J Antimicrob Agents. 2006;28 Suppl 2:115-27.
30. a ed. Barcelona: Masson; 2006.
31. Gotfried MH, Danziger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest. 2001;119:1114-22.